Sage Therapeutics (NASDAQ:SAGE) Lifted to “Hold” at StockNews.com

Sage Therapeutics (NASDAQ:SAGE) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Saturday.

Several other equities analysts have also commented on SAGE. Scotiabank dropped their target price on Sage Therapeutics from $34.00 to $19.00 and set a “sector outperform” rating for the company in a research note on Thursday, April 18th. Oppenheimer dropped their target price on Sage Therapeutics from $25.00 to $17.00 and set a “market perform” rating for the company in a research note on Thursday, April 18th. Wedbush reiterated a “neutral” rating and issued a $24.00 target price on shares of Sage Therapeutics in a research note on Wednesday, April 17th. JPMorgan Chase & Co. upped their price target on Sage Therapeutics from $24.00 to $29.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 26th. Finally, The Goldman Sachs Group dropped their price target on Sage Therapeutics from $28.00 to $19.00 and set a “neutral” rating for the company in a research note on Friday. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $37.72.

Sage Therapeutics Stock Up 0.8 %

NASDAQ SAGE opened at $13.69 on Friday. Sage Therapeutics has a fifty-two week low of $10.92 and a fifty-two week high of $59.99. The stock has a market cap of $822.91 million, a price-to-earnings ratio of -1.51 and a beta of 0.86. The business has a fifty day moving average of $18.56 and a 200-day moving average of $20.64.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.17). Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. The company had revenue of $7.90 million during the quarter, compared to analyst estimates of $5.26 million. During the same period last year, the firm earned ($2.46) earnings per share. The business’s revenue was up 139.4% compared to the same quarter last year. As a group, analysts anticipate that Sage Therapeutics will post -6.3 EPS for the current year.

Institutional Investors Weigh In On Sage Therapeutics

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of Sage Therapeutics by 3.5% in the third quarter. Vanguard Group Inc. now owns 5,208,002 shares of the biopharmaceutical company’s stock valued at $107,181,000 after buying an additional 175,565 shares in the last quarter. Wellington Management Group LLP grew its stake in Sage Therapeutics by 3.3% during the 3rd quarter. Wellington Management Group LLP now owns 6,572,260 shares of the biopharmaceutical company’s stock valued at $135,257,000 after purchasing an additional 208,630 shares in the last quarter. Algert Global LLC acquired a new stake in Sage Therapeutics during the 3rd quarter valued at approximately $1,167,000. Rafferty Asset Management LLC grew its stake in Sage Therapeutics by 197.1% during the 3rd quarter. Rafferty Asset Management LLC now owns 411,904 shares of the biopharmaceutical company’s stock valued at $8,477,000 after purchasing an additional 273,257 shares in the last quarter. Finally, Primecap Management Co. CA grew its stake in Sage Therapeutics by 41.3% during the 3rd quarter. Primecap Management Co. CA now owns 89,850 shares of the biopharmaceutical company’s stock valued at $1,849,000 after purchasing an additional 26,250 shares in the last quarter. Institutional investors and hedge funds own 99.22% of the company’s stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.